NRX Pharmaceuticals (NRXP) EBIT (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of EBIT data on file, last reported at -$4.7 million in Q1 2026.

• On a quarterly basis, EBIT fell 23.26% year-over-year to -$4.7 million in Q1 2026; TTM through Mar 2026 was -$17.1 million, a 4.7% decrease from a year earlier, with the FY2025 full-year figure at -$16.2 million, up 12.31% from the prior year.
• EBIT for Q1 2026 stood at -$4.7 million, down from -$4.6 million in the prior quarter.
• Over the last five years, EBIT for NRXP reached as high as -$2.4 million in Q4 2024 and fell as low as -$15.7 million in Q1 2022.
• Historically, EBIT has averaged -$6.2 million across 5 years, with a median of -$4.7 million in 2026.
• Across the five-year window, EBIT soared 81.33% in 2022 and tumbled 90.13% in 2025, its largest moves.
• Year by year, EBIT stood at -$9.9 million in 2022, then soared by 55.44% to -$4.4 million in 2023, then jumped by 44.8% to -$2.4 million in 2024, then tumbled by 90.13% to -$4.6 million in 2025, then decreased by 2.55% to -$4.7 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$4.7 million in Q1 2026, -$4.6 million in Q4 2025, and -$4.0 million in Q3 2025.